Bharat Biotech and Bilthoven Biologicals B.V. Announce Collaboration to Produce and Supply Oral Polio Vaccines
A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.
Bharat Biotech, a global leader in vaccine and biotherapeutic innovation, and also the largest manufacturer of oral polio vaccines, and Bilthoven Biologicals B.V., (BBio), a wholly owned subsidiary of Serum Institute of India Private Limited, based in the Netherlands, announced a collaboration today, to further strengthen the production and supply security of Oral Polio Vaccines (OPV).
A requisite Agreement has been signed between BBIL and BBio wherein BBIL will procure drug substances for the production of oral polio vaccines to be supplied within India and globally.
Join PSU Connect on WhatsApp now for quick updates! Click here
Read Also : THDCIL Women Team Brings Gold and Silver MedalsThrough this collaboration, BBIL and BBio will jointly obtain the regulatory approvals and licenses required to commercially manufacture OPVs in India for global supplies from drug substances manufactured in the Netherlands at Bilthoven Biologicals.
Read Also : NTPC Talcher Kaniha Concludes 19th Rural Sports Meet (Athletics)
News Must Read
- BEML Ltd Secures Order for 50-Ton Trailer from Defence Ministry
- New CVO Nilabhra Sengupta takes charge at BEL
- Noida International Airport to boost connectivity and Ease of Living: PM Modi
- Sanjay Malhotra appointed as new Governor of RBI
- Defence PSU bags orders worth Rs.634 Crores since...
- MECL and CMPDIL discussed possible collaboration
- Brahmaputra Infra declared No Dividend this year
- Power Minister reviewed Power and Urban Development Sector in Andhra Pradesh
- Harish Duhan recommended for new CMD of SECL
- Punjab to have sufficient urea for rabi season said NFL